The Psychopathology of Acromegaly

Bleuler, M

doi:10.1097/00005053-195101000-00050

Cited by 24 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings in this study lend support to the appraisal of pathophysiological links in endocrine and psychiatric disorders, as pioneered by Harvey Cushing in endocrinology [26] and Manfred Bleuler [27] in psychiatry. This appraisal may result in conceptual models more in keeping with the complexity of psychoneuroendocrine interactions and in therapeutic efforts yielding more lasting relief, both in Cushing's disease and nonendocrine major depression.…”

Section: Discussionsupporting

confidence: 72%

Clinical Correlates of Major Depression in Cushing’s Disease

Sonino

Fava²,

Raffi³

et al. 1998

Psychopathology

129

View full text Add to dashboard Cite

Major depression is a common, life-threatening complication of Cushing’s syndrome, with no significant differences between pituitary-dependent and -independent forms. Little is known about the clinical correlates of depression; in particular, whether patients with Cushing’s disease and major depression show some clinical features that are distinctive compared to those who are not depressed. The occurrence of major depression according to DSM-IV criteria was ascertained in 162 patients with pituitary-dependent Cushing disease. Major depression occurred in 88 of the patients (54%). It was significantly associated with older age, female sex, higher pretreatment urinary cortisol levels, relatively more severe clinical condition, and absence of pituitary adenoma. Patients with Cushing’s disease and depression appeared to suffer from a more severe form of illness, both in terms of cortisol production and clinical presentation, compared to those who were not depressed. Because of these connections, the presence of depression is an important clinical feature that should not be neglected. The findings in this study may have implications for a better understanding of the pathophysiological role of depression associated with medical illness.

show abstract

Section: Discussionsupporting

confidence: 72%

Clinical Correlates of Major Depression in Cushing’s Disease

Sonino

Fava²,

Raffi³

et al. 1998

Psychopathology

129

View full text Add to dashboard Cite

show abstract

“…Clinical descriptions of the comportment of acromegalics by physicians are also consistent with our findings of decreased locomotion after administration of GRF (12). One additional comment concerning the dose of GRF holds true regardless of which results are ultimately confirmed.…”

supporting

confidence: 86%

Effects of Growth Hormone-Releasing Factor in the Brain

Wehrenberg¹,

Ehlers²

1986

Science

View full text Add to dashboard Cite

show abstract

“…Our results demonstrate that administration of GRF in the lateral ventricles of the brain increases plasma GH Clinical descriptions of the comportment of acromegalics by physicians are also consistent with our findings of decreased locomotion after administration of GRF (12). One additional comment concerning the dose of GRF holds true regardless of which results are ultimately confirmed.…”

supporting

confidence: 88%

Response : Effects of Growth Hormone-Releasing Factor in the Brain

Tannenbaum

1986

Science

View full text Add to dashboard Cite

The intracerebroventricular administration of 10 ,ug of GRF resulted in a significant increase (P < 0.01) in circulating plasma GH concentrations 30 minutes after injection (Fig. 1). In addition, neither GRF nor saline altered the 3-hour pulsatile pattem of spontaneous GH secretion. EEG recordings indicated that the time to onset of slow wave sleep was significantly less (P < 0.05) in the GRF-treated rats (9 ± 1 minute) than in the saline-treated ones (15 ± 2 minutes). Similarly, the amount of time spent in slow wave sleep was significantly greater in the GRF-treated rats (24 ± 4% versus 13 ± 4%, P < 0.05). Intracerebroventricular GRF also significantly decreased (P < 0.05) mean locomotor activity (Fig. 2) Clinical descriptions of the comportment of acromegalics by physicians are also consistent with our findings of decreased locomotion after administration of GRF (12). One additional comment concerning the dose of GRF holds true regardless of which results are ultimately confirmed. Isolation of rat GRF from the hypothalamus (13) indicates that there is approximately 100 to 500 pg of GRF per hypothalamus. Thus, the doses of GRF administered in the present study and in Tannenbaum's study (4) are on the order of 104 to 105 times greater than the total hypothalamic content. Although one can argue that the amount of GRF that actually reaches a particular neuronal site is unknown, the dilution factor is probably not on the order of 104 to 105. We believe it is unlikely that GRF regulates its own neurosecretion through an "ultrashort-loop" negative feedback mechanism, but suggestions that GRF may have important neurotransmitter or neuromodulator roles within the brain are indeed open.

show abstract

The Psychopathology of Acromegaly

Cited by 24 publications

References 0 publications

Clinical Correlates of Major Depression in Cushing’s Disease

Clinical Correlates of Major Depression in Cushing’s Disease

Effects of Growth Hormone-Releasing Factor in the Brain

Response : Effects of Growth Hormone-Releasing Factor in the Brain

Contact Info

Product

Resources

About